EGFR and non-small cell lung carcinoma: These characteristics of third‐generation EGFR‐TKIs have led to their significant efficacy and decreased toxicity in clinical trials,17, 18 and osimertinib has been approved for the treatment of EGFR‐positive NSCLC patients.19